Higher pre-NAC TIL levels have been associated with higher pathological complete response (pCR) rates and longer survival than have lower levels in triple-negative (TN) and human epidermal growth factor receptor 2 (HER2)+ breast cancers but not in hormone receptor (HR)+ and HER2− (luminal) breast cancers [11]. The gene discussed is NR4A1; the disease is breast carcinoma.